Courtesy of Benzinga.
Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) shares are trading lower by $8.50, or 56 percent, at $6.50 in Monday’s session.
Before the open, the company announced top-line results from Phase 2 Star 1 trial of ZYN002 for treatment of adult epileptic patients with focal seizures didn’t meet its primary endpoint.
See Also: What Zynerba’s Flop Means For CBD Therapies And GW Pharmaceuticals
After a lower open, Zynerba had a brief bounce to $6.75 before continuing its move lower. So far, the ensuing decline has taken the stock to $5.93, but rebounded back into the mid-$6.00 handle. That low comes in just above March 2015 low ($5.75).
Its all-time low was made the month prior at $4.64.
Posted-In: Technicals Intraday Update Movers Trading Ideas